Skip to main content
  • ShortCut Device Successfully Splits Failed Bioprosthetic Valve Leaflets in ViV TAVR – First-in-Human Study

    The first dedicated transcatheter leaflet-splitting device demonstrated safety and successfully prevented coronary obstruction after transcatheter aortic valve replacement (TAVR) in a first-in-human trial of patients with failed bioprosthetic valves.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details